中国基层医药
中國基層醫藥
중국기층의약
Chinese Journal of Primary Medicine and Pharmacy
2015年
23期
3594-3596
,共3页
金洁娜%林昭宇%孙慧燕%余玉慧%刘隽%诸乐飞
金潔娜%林昭宇%孫慧燕%餘玉慧%劉雋%諸樂飛
금길나%림소우%손혜연%여옥혜%류준%제악비
糖尿病肾病%细胞因子类%蛋白尿%氟伐他汀
糖尿病腎病%細胞因子類%蛋白尿%氟伐他汀
당뇨병신병%세포인자류%단백뇨%불벌타정
Diabetic nephropathy%Cytokines%Proteinuria%Fluvastatin
目的:探讨氟伐他汀治疗早期糖尿病肾病临床效果,为临床诊治提供参考。方法选择糖尿病肾病患者90例,按照数字表法随机分为观察组与对照组,观察组50例,对照组40例。对照组常规降糖治疗,并使用缬沙坦治疗,观察组在对照组基础上联合氟伐他汀治疗。比较两组治疗有效率、尿清蛋白排泄率、炎性指标、血肌酐等指标及不良反应。结果观察组有效率为90.00%,明显高于对照组的75.00%,差异有统计学意义(χ2=4.325,P <0.05);观察组治疗后 BUN、UAER、TC、TG、LDL 分别为(6.54±1.24)mmol/L、(40.43±4.21)μg/min、(3.81±0.47)mmol/L、(2.51±0.34)mmol/L、(2.41±0.64)mmol/L,改善明显优于对照组,差异均有统计学意义(t =5.547、5.225、5.457、4.957、5.339,均 P <0.05);观察组治疗后 CRP、IL-6、IL-18、TNF-α分别为(4.14±0.87)mg/L、(88.17±8.54)pg/mL、(139.64±9.48)ng/L、(40.17±5.22)ng/L,改善明显优于对照组,差异均有统计学意义(t =6.914、6.357、5.847、7.054,均 P <0.05)。结论氟伐他汀治疗早期糖尿病肾病临床效果好,利于改善炎性因子及尿蛋白,保护肾功能,值得临床推广应用。
目的:探討氟伐他汀治療早期糖尿病腎病臨床效果,為臨床診治提供參攷。方法選擇糖尿病腎病患者90例,按照數字錶法隨機分為觀察組與對照組,觀察組50例,對照組40例。對照組常規降糖治療,併使用纈沙坦治療,觀察組在對照組基礎上聯閤氟伐他汀治療。比較兩組治療有效率、尿清蛋白排洩率、炎性指標、血肌酐等指標及不良反應。結果觀察組有效率為90.00%,明顯高于對照組的75.00%,差異有統計學意義(χ2=4.325,P <0.05);觀察組治療後 BUN、UAER、TC、TG、LDL 分彆為(6.54±1.24)mmol/L、(40.43±4.21)μg/min、(3.81±0.47)mmol/L、(2.51±0.34)mmol/L、(2.41±0.64)mmol/L,改善明顯優于對照組,差異均有統計學意義(t =5.547、5.225、5.457、4.957、5.339,均 P <0.05);觀察組治療後 CRP、IL-6、IL-18、TNF-α分彆為(4.14±0.87)mg/L、(88.17±8.54)pg/mL、(139.64±9.48)ng/L、(40.17±5.22)ng/L,改善明顯優于對照組,差異均有統計學意義(t =6.914、6.357、5.847、7.054,均 P <0.05)。結論氟伐他汀治療早期糖尿病腎病臨床效果好,利于改善炎性因子及尿蛋白,保護腎功能,值得臨床推廣應用。
목적:탐토불벌타정치료조기당뇨병신병림상효과,위림상진치제공삼고。방법선택당뇨병신병환자90례,안조수자표법수궤분위관찰조여대조조,관찰조50례,대조조40례。대조조상규강당치료,병사용힐사탄치료,관찰조재대조조기출상연합불벌타정치료。비교량조치료유효솔、뇨청단백배설솔、염성지표、혈기항등지표급불량반응。결과관찰조유효솔위90.00%,명현고우대조조적75.00%,차이유통계학의의(χ2=4.325,P <0.05);관찰조치료후 BUN、UAER、TC、TG、LDL 분별위(6.54±1.24)mmol/L、(40.43±4.21)μg/min、(3.81±0.47)mmol/L、(2.51±0.34)mmol/L、(2.41±0.64)mmol/L,개선명현우우대조조,차이균유통계학의의(t =5.547、5.225、5.457、4.957、5.339,균 P <0.05);관찰조치료후 CRP、IL-6、IL-18、TNF-α분별위(4.14±0.87)mg/L、(88.17±8.54)pg/mL、(139.64±9.48)ng/L、(40.17±5.22)ng/L,개선명현우우대조조,차이균유통계학의의(t =6.914、6.357、5.847、7.054,균 P <0.05)。결론불벌타정치료조기당뇨병신병림상효과호,리우개선염성인자급뇨단백,보호신공능,치득림상추엄응용。
Objective To investigate clinical effect of fluvastatin in the treatment of early diabetic nephropa-thy,to provide a reference for clinical treatment.Methods 90 patients with diabetic nephropathy were selected,the patients were divided into observation group(50 cases)and control group(40 cases).Conventional hypoglycemic ther-apy used in the control group,and valsartan treatment also used.The observation group received fluvastatin on the basis of treatment of control group.The efficacy,urinary albumin excretion rate,inflammatory markers,serum creatinine and other indicators and adverse reactions were compared.Results The effective rate of the observation group was 90.00%,which was significantly higher than 75.00% of the control group,the difference was statistically significant (χ2 =4.325,P <0.05).After treatment,the BUN,UAER,TC,TG,LDL of the observation group were (6.54 ± 1.24)mmol/L,(40.43 ±4.21)μg/min,(3.81 ±0.47)mmol/L,(2.51 ±0.34)mmol/L,(2.41 ±0.64)mmol/L, the improvement was better than the control group,the differences were statistically significant (t =5.547,5.225, 5.457,4.957,5.339,all P <0.05).After treatment,the CRP,IL -6,IL -18,TNF -αin the observation group and control group were significantly improved compared with before treatment,the differences were statistically significant (P <0.05 ).After treatment,the CRP,IL -6,IL -18,TNF -αlevels of the observation group were (4.14 ± 0.87)mg/L,(88.17 ±8.54)pg/mL,(139.64 ±9.48)ng/L,(40.17 ±5.22)ng/L,the improvement was better than the control group,the differences were statistically significant (t =6.914,6.357,5.847,7.054,all P <0.05 ). Conclusion Fluvastatin in the treatment of early diabetic nephropathy has good effect,which will help to improve inflammatory cytokines and proteinuria and protect renal function,it is worthy of clinical application.